Bayer Schering Pharma paves the way to the next important oral contraceptive milestone
|
04 December 2007 |
New Phase III Trial Results for Rivaroxaban
|
12 November 2007 |
Bayer Temporarily Suspends Global Trasylol® Marketing
|
05 November 2007 |
Nexavar® Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
|
31 October 2007 |
Bayer Issues Additional Guidance to Physicians on Trasylol®
|
26 October 2007 |
Three-year analysis demonstrates continued robust treatment effect of Alemtuzumab compared to Rebif
|
16 October 2007 |
Positive Phase 2 Results for the VEGF Trap-Eye
|
01 October 2007 |
Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
|
28 September 2007 |
Start of the TALENT Study - a Unique Antihypertensive Study in Europe
|
27 September 2007 |
Campath® Include First-line Treatment for Leading Form of Adult Leukemia
|
21 September 2007 |
FDA Advisory Committees Recommend Continued US Marketing Authorization for Trasylol
|
13 September 2007 |
Bayer intends to delist from the New York Stock Exchange
|
09 September 2007 |